Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biobusiness Briefs
  • Published:

Regulatory watch

Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Issues with clinical development programmes of products for psychiatry or neurology indications reviewed by the European Medicines Agency between 1995 and 2014.

Acknowledgements

The authors are grateful to M. Berntgen for his support in this project and would also like to thank O. Collignon for advice on the statistical methodology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Florence Butlen-Ducuing.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Data and analysis (PDF 609 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butlen-Ducuing, F., Pétavy, F., Guizzaro, L. et al. Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Nat Rev Drug Discov 15, 813–814 (2016). https://doi.org/10.1038/nrd.2016.237

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.237

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research